[Effect of trimetazidine and perindopril on myocardial function and metabolism in patients with low cardiac output during postinfarction period].
To investigate effects of trimetazidine and perindopril on myocardial function and metabolism in patients with cardiac failure after myocardial infarction. A comparative study was mode of the effects of 6-month therapy with perindopril, trimetazidine alone and in combination on clinical symptoms, left ventricular function and perfusion, glucose utilization, excretion and utilization of fatty acids in the zones of postinfarction scar, periinfarction ischemia and in without infarction changes. Combined treatment with the ACE inhibitor and trimetazidine produced positive clinical and functional-metabolic shifts in postmyocardial infarction patients with cardiac failure. The addition to the program of mild cardiac failure treatment early after myocardial infarction of an ACE inhibitor and a cytoprotective drug (trimetazidine) promotes more complete clinical compensation of the patients.